Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
Open Access
- 28 February 2021
- journal article
- review article
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 2 (1), 1-25
- https://doi.org/10.37349/etat.2021.00030
Abstract
The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in patient prognosis. Disappointingly, the success of ICI therapy in NSCLC has not been fully replicated in other thoracic malignancies as small cell lung cancer (SCLC), malignant pleural mesothelioma (MPM), and thymic epithelial tumors (TETs), due to the peculiar biological features of these disease and to the difficulties in the conduction of well-designed, biomarker-driven clinical trials. Therefore, combination strategies of ICIs plus conventional therapies (either chemotherapy, alternative ICIs or targeted agents) have been implemented. Although first approvals of ICI therapy have been recently granted in SCLC and MPM (in combination with chemotherapy and different ICIs), results remain somewhat modest and limited to a small proportion of patients. This work reviews the trial results of ICI therapy in mesothelioma, SCLC, and TETs and discusses the potential of combining ICIs with old drugs.Keywords
This publication has 128 references indexed in Scilit:
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialThe Lancet Oncology, 2013
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyProceedings of the National Academy of Sciences of the United States of America, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509Journal of Thoracic Oncology, 2011
- Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial TumorsJournal of Clinical Oncology, 2011
- A small-cell lung cancer genome with complex signatures of tobacco exposureNature, 2009
- Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGFBlood, 2007
- Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3Lung Cancer, 2004
- Primary thymic carcinomaThe Annals of Thoracic Surgery, 2002
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996